Amitriptyline was administered intraperitoneally every day for 10 weeks (0.5 mg/mouse). Inhibition of hepatic steatosis. Suppressed SP1 and ceramide formation, reduction of proinflammatory cytokines, suppressing hepatic inflammation (95). Here, SP1 is linked to fatty liver disease.